Companies › Altimmune
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Gastroenterology, Metabolic and endocrine; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Pemvidutide GLP-1 and glucagon receptor dual agonist | GLP1R, GCGR | Phase 3 | Metabolic Dysfunction-Associated Steatohepatitis (MASH); Alcohol-associated Liver Disease | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07009860 | Pemvidutide | Phase 2 | Alcohol-associated Liver Disease | Gastroenterology | Sep 2027 |
| NCT07795164 | Pemvidutide | Phase 3 | Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Metabolic and endocrine | Dec 2028 |
Cash and short-term investments of $326m on 2026-06-30; operating cash outflow about $92m a year; runway about 43 months at that burn, to Jan 2030; 2 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 10 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
VectivBio Kailera Camurus Ascendis Pharma Bone Diseases BioXTek
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.